Featured

CRATERs on the tumor cell surface are hubs for antitumor immunity

Cancer immunology studies are often performed using mouse models or tumor samples from patients, but these models do not provide ideal opportunities to study immune cells as they interact with endogenous tumors. To visualize tumor–immune interactions...

Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures

Using spatial multiomics, Cakmak et al. profiled 642 adult-type diffuse gliomas and identified tertiary lymphoid structures (TLSs) in 15% of the tumors. TLS-positive gliomas showed decreased neural tu...

A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice

Cao, Shen, and Fu et al. created ProCTLA-4, a prodrug comprising a misfolded anti-CTLA-4 Ab, correctable by MMP cleavage in the TME. ProCTLA-4 exhibited high-affinity binding in TME (not LN/spleen), ...

Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia

Sandén and Landberg et al. demonstrated that lymphoid surface protein SLAMF6 is overexpressed in 60% of primitive AML cells across all subtypes. High SLAMF6 expression correlated with enrichment of na...

Biselective remodeling of the melanoma tumor microenvironment prevents metastasis and enhances immune activation in mouse models

Afratis et al. focused on disrupting key extracellular matrix (ECM) pathways in the TME by engineering dual-targeting decoys (glycosylated and non-glycosylated lysyl oxidase [LOX] propeptide-Fc) that ...

See all for this week

Previous Digests

2025 marks a special milestone for ACIR

October 27, 2025

This year, 2025, marks a special milestone: ACIR’s 10th anniversary! And we celebrate it with the announcement of a leadership transition. Dear Readers, The idea for ACIR was born in early 2015, just a few months after my son...

Lipid formulation replacement reroutes mRNA to the spleen for improved immune activation

October 22, 2025

The spleen has gained interest as a vaccination target, as high uptake of therapeutic mRNA cancer vaccines by antigen-presenting cells (APCs) is needed for therapeutic efficacy. However, current formulations of mRNA vaccines contain lipid nanoparticles (LNPs) that accumulate in...

Immunotherapy efficacy in absence of antigen presentation? How CD4+ T cells mediate responses

October 15, 2025

The antitumor efficacy of cancer immunotherapy often relies heavily on CD8+ and CD4+ T cell recognition of tumor antigens presented on MHC molecules. However, investigating settings with low or no tumor MHC expression, Kim and Haerr et al. found...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials